FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: Synergetics USA

Sort
E.g., 2013-05-25
E.g., 2013-05-25
Enter a comma separated list of user names.

RPRX, Repros Therapeutics Inc.

** RPRX provided top line results for the end of dosing analysis on its Phase 2 clinical study of Androxal in hypogonadal men with type 2 diabetes. Many men with secondary hypogonadism also have type 2 diabetes.

***********************

SURG, Synergetics USA, Inc.

SURG, Synergetics USA, Inc.

** SURG reported that for the fourth quarter fiscal 2011, its net income rose 100% to $2.0 million and its sales rose 21% to a record $15.8 million compared to the same period in the prior year.

SURG is a leading supplier of precision surgical devices. SURG's primary focus is on the disciplines of ophthalmology and neurosurgery.

Synergetics USA, Inc. (Nasdaq:SURG) announced that it will host a conference call the morning of Thursday, March 10, 2011, at 10:30 a.m. Eastern time to review the Company's results for the fiscal second quarter ended January 31, 2011. A news release announcing the second quarter's results will be issued on Wednesday, March 9, 2011, after market close.

Synergetics USA, Inc. (NASDAQ:SURG) announced that it will host a conference call the morning of Wednesday, December 15, 2010, at 10:30 a.m. Eastern time to review the Company's results for the fiscal first quarter ended October 31, 2010. A news release announcing the first quarter's results will be issued on Tuesday, December 14, 2010, after market close.

Synergetics USA, Inc. (NASDAQ:SURG) recently announced that David M. Hable, President and Chief Executive Officer, will make a presentation at the Craig-Hallum Capital Group 2010 Alpha Select Conference on Wednesday, October 6, 2010.

The Conference will be held at The Roosevelt Hotel in New York City and Mr. Hable’s presentation is scheduled for 3:25 p.m. Eastern time.

ADVERTISE WITH US